Compare KeyCorp (KEY) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KeyCorp vs Merck & Co., Inc. — how do they compare? KeyCorp trades at $19.98 (market cap $21.45B), while Merck & Co., Inc. trades at $145.83 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 16.4× KeyCorp's market cap, and KeyCorp pays the higher dividend (4.08%). Which is the better fit depends on your goals — on Pluang, investors hold KeyCorp for 66 Days and Merck & Co., Inc. for 98 Days on average.
| KEY | MRK | |
|---|---|---|
Market Cap | $21.45B | $351.28B |
Volume | 19,450,846 | 7,969,665 |
Sector | Financials | Health |
52-Week High | $23.99 | $156.43 |
52-Week Low | $16.78 | $82.49 |
Typical Hold Time | 66 Days | 98 Days |
Enterprise Value | $34.63B | $398.04B |
Dividend Yield | 4.08% | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KeyCorp (KEY) trades at $19.985, up 0.78% on the day, with strong fundamental metrics including a P/E of 11.75 and net income margin of 26.72%. The stock shows consistent earnings beats in recent quarters and maintains a solid dividend yield. Technical indicators suggest bearish momentum despite neutral oscillators, while analyst consensus remains strongly bullish with a $25.00 price target representing 25% upside potential from current levels.
KEY presents a compelling value opportunity with attractive valuation multiples and strong profitability, though technical weakness and frozen dividend payments pose near-term concerns. The bank's improved revenue guidance for 2026 and aggressive share buyback program support EPS growth, while interest rate sensitivity remains a key risk factor for the regional banking sector.
Merck (MRK) trades at $145.6, up 1.97% today, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company is expanding its oncology pipeline through the acquisition of Terns Pharmaceuticals. Revenue growth is steady, with 2025 revenue at $65.01B and net income of $18.25B, though 2026 projections show a significant drop in net income to $3.2B. The stock is supported by a high analyst buy consensus of 68.42% and a price target of $158.78.
The outlook for MRK is mixed; strong earnings beats and strategic acquisitions provide upside potential, but high valuation ratios and a projected earnings decline in 2026 pose risks. Investors should weigh the company's robust profitability and analyst support against execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KeyCorp
With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
